Senate Finds U Minnesota Surgeon Took $1.2 Million From Medtronic

Star Tribune.com has:

Consulting Flap Drives U Surgeon From Board

"Polly, the head of the U's spine surgery department, has been a target in a congressional investigation exploring the financial relationships between doctors and medical device makers. Initiated by Sen. Charles Grassley, R-Iowa, the probe found Polly was paid $1.2 million between 2003 and 2007 by the Fridley-based medical technology company for consulting, expenses and honoraria.

Such relationships are common -- and legal -- in the $140 billion medical technology industry. Doctors offer medical device makers advice on how to improve products; sometimes they are paid royalties for inventions commercialized by device manufacturers.

Grassley's investigation revealed that by 2007 Medtronic paid Polly $4,750 a day, or $594 an hour, with an annual cap of $400,000, and that Polly gave congressional testimony on spine surgery research without disclosing his relationship with Medtronic."

Read the whole article


For analysis of this phenomena - IE: What Medical Ethics Really Means Today - see University Diaries:

Dr Polly And Fair Market Value

"Well, we know that he billed Medtronic at these rates for a Medtronic person simply entering his office. He billed them when he called them to chat, billed them when he did this, when he did that… Again, it’s very hard to quantify these things. Does a whore charge for taking off her bra and making small talk? Or is she just charging for the act itself?"

Soulful Sepulcher On APA Funding: Who Bought Your Thoughts?

Soulful Sepulcher has another Mind Blowing report on Who, owns, or would Like to own, your every thought, along with every nickel on the planet. Be patient if the page takes time to load.

There's THAT MUCH Drug Company Influence propping the Mental Hygienists: the crowd who are Still working the same THEORIES which brought us the Holocaust (1).

2007 APA Meeting Pharma Funding Disclosure List That Will Blow Your Mind

The Drug Companies underwriting this Symptom Bashing Bucket of Bio-$cience are laid out in:

http://www.psychconfllicts.org/pdfs/2007 APA_Program_2007.pdf

Grab a copy for yourself. Share it with your friends and neighbors, Before, They are tempted to Trust any of these Incurable Incompetents. And if you don't think they're Incurably Incompetent, try finding something they've ever Cured. Then hit our label Side Effects, and do a quick summation of Cost V Benefit.


John Mack at Pharma Marketing Blog has two Stellar posts we recommend to shed further light on the Whatever you want to call it, conflicting today's Academic Medicine.

In Medical Publishing, Is Disclosure Enough?

Nissen Puts Stake Through ACCME's Heart At Senate Hearing On Industry Funded CME


And of possibly, tangentially related (CME) Interest, we have:

Penn & Teller Reveal Stage(d) Magic


Ahhh,nd, ...... yet one More necrotizing nostrum - this one's called Asenapine - appears poised to invade America's medicine cabinet.

Shearlings Got Plowed

Call Congress. Cut the Public Funding/Protection Off, All of it.

$253K GSK DRUG MONEY: Another Emory Psych Prof EXPOSED

University Diaries has:

Another Shameless Emory Professor

" … is caught out in conflict of interest. This time the health of pregnant women was compromised as the guy didn’t tell Emory that he was a paid agent of Glaxo even as he was publishing research on the effects of their drug, Paxil, on expectant mothers.

But whaddaya expect? When the chair of your department is Charles Nemeroff, the sky’s the limit. There will be more such stories coming out of Emory." ......

UD has more. Go read her report.

BTW: This Prof was also a guest on the Outed ($1.3 Million Dollars in Drug Money) Fred Goodwin's "Infinite Mind" infomercial.

“,.... it didn’t occur to me that my doing what every other expert in the field does might be considered a conflict of interest,” Goodwin said.

Thank You Sen Grassley, & UD.

Chief UCLA Spine Dr: $459K In Conflicting Payments, LIED About

The WSJ has:

Grassley Points To Another Academic Doctor's Industry Pay

..... Companies that made payments such as consulting and speaking fees to Wang included medical-device makers Medtronic and FzioMed and the DePuy unit of Johnson & Johnson. Grassley says Wang “consistently checked no” on UCLA disclosure forms when asked whether he had received income of $500 or more from companies funding his clinical research. All three companies were sponsoring research by Wang at the time of the payments, WSJ reports. Grassley says UCLA told him that Wang “erred in completing” the disclosures. .....

Erred? In completing the disclosures?

This goes back to our prima facia contention that:

1: These people are too Stupid to retain a physician's license.
2: They're Not too stupid, they're far Worse.

And before anyone is tempted to equate these sorts of non disclosed highjinks in medicine with those in the banking and securities sector:

Being Robbed, even of your life savings, is Not on the same footing with being Dead, due to Medical Money Acey Duecy.

Once again: Thank You Senator Grassley.

GSK: Senate Finds ANOTHER Possible $80,000 in Undisclosed DRUG MONEY to Dr Wagner

The WSJ has:

Grassley Ups Total Of Undisclosed Fees Paid To Prof By Glaxo

" ..... Wagner is the vice chairman of the psychiatry department at the University of Texas Medical Branch at Galveston, and at one point, served on the school’s conflict-of-interest committee. A spokesman for UTMB Galveston said Ms. Wagner wasn’t available to comment.

If her outside funds weren’t reported to the National Institutes of Health, which funded the Paxil study, it could create problems for UT in getting future NIH grants. The school has received more than $5 billion in NIH funds since 2000."

There's a 48 page PDF that comes with this WSJ report, so get yourself one while the getting's good.

And, One click today has Dr Karen Dineen Wagner Still listed on the Scientific Council of NARSAD

Too Many Kids On Psych Drugs ~ Repost

In light of the Govt Interest following the deaths of 4 year old Rebecca Riley and 7 year old Gabriel Myers we're reposting these vids.

Child Psychiatry has recently undergone a 4000% Increase in the Diagnosis of Childhood Bipolar Disorder: with these tragic and needless consequences. Diagnosis CURES NOTHING.

Doctors Biederman, Wilens and Spencer from Harvard Med School are the driving force behind this Explosion in young children being Diagnosed and Drugged. Doctors Biederman, Wilens and Spencer received over $4 Million Dollars, from the makers of Psychiatric Drugs.

You do the math.

Too Many Kids On Psych Drugs?







For background on Dr Joe "Short Fuse" Biederman return to:

InVivo for:

Harvard's Biederman: After Me There Is Only God

And to Really get grounded in this Drug Money Fiasco that's slugging little kids see:

The Alliance For Human Research Protection for:

Biederman Search Results

Ed Silverman's Pharmalot for:

Biederman Search Results


There are 7000 Child Psychiatrists in America. The entire 'Mental Health' Industry will be justifying its dope peddling to Children, Your Children, based on the work of Harvard's $4.2 Million Dollar Biederman crew, ...... for Decades to come.

S. 301 Physician Payments Sunshine Act Of 2009

On Jan 22 2009 S. 301 was introduced.

http://thomas.loc.gov/cgi-bin/query/z?c111:S.301:

has:

Physician Payments Sunshine Act of 2009 (Introduced in Senate)

S 301 IS

111th CONGRESS 1st Session

S. 301

To amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP.

IN THE SENATE OF THE UNITED STATES

January 22, 2009

Mr. GRASSLEY (for himself, Mr. KOHL, and Ms. KLOBUCHAR) introduced the following bill; which was read twice and referred to the Committee on Finance

---

A BILL

To amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the `Physician Payments Sunshine Act of 2009'.

SEC. 2. TRANSPARENCY REPORTS AND REPORTING OF PHYSICIAN OWNERSHIP OR INVESTMENT INTERESTS.

Part A of title XI of the Social Security Act (42 U.S.C. 1301 et seq.) is amended by inserting after section 1128F the following new section:

`SEC. 1128G. TRANSPARENCY REPORTS AND REPORTING OF PHYSICIAN OWNERSHIP OR INVESTMENT INTERESTS.

`(a) Transparency Reports-

`(1) PAYMENTS OR OTHER TRANSFERS OF VALUE-

`(A) IN GENERAL- Except as provided in subsection (e), on March 31, 2011, and on the 90th day of each calendar year beginning thereafter, any applicable manufacturer that provides a payment or other transfer of value to a covered recipient (or to an entity or individual at the request of or designated on behalf of a covered recipient), shall submit to the Secretary, in such electronic form as the Secretary shall require, the following information with respect to the preceding calendar year:

`(i) The name of the covered recipient.

`(ii) The business address of the covered recipient and, in the case of a covered recipient who is a physician, the specialty and Medicare billing number of the covered recipient.

`(iii) The value of the payment or other transfer of value.

`(iv) The dates on which the payment or other transfer of value was provided to the covered recipient.

`(v) A description of the form of the payment or other transfer of value, indicated (as appropriate for all that apply) as--

`(I) cash or a cash equivalent;

`(II) in-kind items or services;

`(III) stock, a stock option, or any other ownership interest, dividend, profit, or other return on investment; or

`(IV) any other form of payment or other transfer of value (as defined by the Secretary).

`(vi) A description of the nature of the payment or other transfer of value, indicated (as appropriate for all that apply) as--

`(I) consulting fees;

`(II) compensation for services other than consulting;

`(III) honoraria;

`(IV) gift;

`(V) entertainment;

`(VI) food;

`(VII) travel;

`(VIII) education;

`(IX) research;

`(X) charitable contribution;

`(XI) royalty or license;

`(XII) current or prospective ownership or investment interest;

`(XIII) compensation for serving as faculty or as a speaker for a continuing medical education program;

`(XIV) grant; or

`(XV) any other nature of the payment or other transfer of value (as defined by the Secretary).

`(vii) If the payment or other transfer of value is related to marketing, education, or research specific to a covered drug, device, biological, or medical supply, the name of that covered drug, device, biological, or medical supply.

`(viii) Any other categories of information regarding the payment or other transfer of value the Secretary determines appropriate.

`(B) AGGREGATE REPORTING- Information submitted by an applicable manufacturer under subparagraph (A) shall include the aggregate amount of all payments or other transfers of value provided by the applicable manufacturer to covered recipients (and to entities or individuals at the request of or designated on behalf of a covered recipient) during the preceding year.

`(C) SPECIAL RULE FOR CERTAIN PAYMENTS OR OTHER TRANSFERS OF VALUE- In the case where an applicable manufacturer provides a payment or other transfer of value to an entity or individual at the request of or designated on behalf of a covered recipient, the applicable manufacturer shall disclose that payment or other transfer of value under the name of the covered recipient.

`(2) PHYSICIAN OWNERSHIP- In addition to the requirement under paragraph (1)(A), on March 31, 2011, and on the 90th day of each calendar year beginning thereafter, any applicable manufacturer or applicable group purchasing organization shall submit to the Secretary, in such electronic form as the Secretary shall require, the following information regarding any ownership or investment interest (other than an ownership or investment interest in a publicly traded security and mutual fund, as described in section 1877(c)) held by a physician (or an immediate family member of such physician (as defined for purposes of section 1877(a))) in the applicable manufacturer or applicable group purchasing organization during the preceding year:

`(A) The dollar amount invested by each physician holding such an ownership or investment interest.

`(B) The value and terms of each such ownership or investment interest.

`(C) Any payment or other transfer of value provided to a physician holding such an ownership or investment interest (or to an entity or individual at the request of or designated on behalf of a physician holding such an ownership or investment interest), including the information described in clauses (i) through (viii) of paragraph (1)(A), except that in applying such clauses, `physician' shall be substituted for `covered recipient' each place it appears.

`(D) Any other information regarding the ownership or investment interest the Secretary determines appropriate.

`(b) Penalties for Noncompliance-

`(1) FAILURE TO REPORT-

`(A) IN GENERAL- Subject to subparagraph (B), except as provided in paragraph (2), any applicable manufacturer or applicable group purchasing organization that fails to submit information required under subsection (a) in a timely manner in accordance with rules or regulations promulgated to carry out such subsection, shall be subject to a civil money penalty of not less than $1,000, but not more than $10,000, for each payment or other transfer of value or ownership or investment interest not reported as required under such subsection. Such penalty shall be imposed and collected in the same manner as civil money penalties under subsection (a) of section 1128A are imposed and collected under that section.

`(B) LIMITATION- The total amount of civil money penalties imposed under subparagraph (A) with respect to each annual submission of information under subsection (a) by an applicable manufacturer or applicable group purchasing organization shall not exceed $150,000.

`(2) KNOWING FAILURE TO REPORT-

`(A) IN GENERAL- Subject to subparagraph (B), any applicable manufacturer or applicable group purchasing organization that knowingly fails to submit information required under subsection (a) in a timely manner in accordance with rules or regulations promulgated to carry out such subsection, shall be subject to a civil money penalty of not less than $10,000, but not more than $100,000, for each payment or other transfer of value or ownership or investment interest not reported as required under such subsection. Such penalty shall be imposed and collected in the same manner as civil money penalties under subsection (a) of section 1128A are imposed and collected under that section.

`(B) LIMITATION- The total amount of civil money penalties imposed under subparagraph (A) with respect to each annual submission of information under subsection (a) by an applicable manufacturer or applicable group purchasing organization shall not exceed $1,000,000.

`(3) USE OF FUNDS- Funds collected by the Secretary as a result of the imposition of a civil money penalty under this subsection shall be used to carry out this section.

`(c) Procedures for Submission of Information and Public Availability-

`(1) IN GENERAL-

`(A) ESTABLISHMENT- Not later than November 1, 2009, the Secretary shall establish procedures--

`(i) for applicable manufacturers and applicable group purchasing organizations to submit information to the Secretary under subsection (a); and

`(ii) for the Secretary to make such information submitted available to the public.

`(B) DEFINITION OF TERMS- The procedures established under subparagraph (A) shall provide for the definition of terms (other than those terms defined in subsection (g)), as appropriate, for purposes of this section.

`(C) PUBLIC AVAILABILITY- The procedures established under subparagraph (A)(ii) shall ensure that, not later than September 30, 2011, and on June 30 of each calendar year beginning thereafter, the information submitted under subsection (a) with respect to the preceding calendar year is made available through an Internet website that--

`(i) is searchable and is in a format that is clear and understandable;

`(ii) contains information that is presented by the name of the applicable manufacturer or applicable group purchasing organization, the name of the covered recipient, the business address of the covered recipient, the specialty of the covered recipient, the value of the payment or other transfer of value, the date on which the payment or other transfer of value was provided to the covered recipient, the form of the payment or other transfer of value, indicated (as appropriate) under subsection (a)(1)(A)(v), the nature of the payment or other transfer of value, indicated (as appropriate) under subsection (a)(1)(A)(vi), and the name of the covered drug, device, biological, or medical supply, as applicable;

`(iii) contains information that is able to be easily aggregated and downloaded;

`(iv) contains a description of any enforcement actions taken to carry out this section, including any penalties imposed under subsection (b), during the preceding year;

`(v) contains background information on industry-physician relationships;

`(vi) in the case of information submitted with respect to a payment or other transfer of value described in subsection (e), lists such information separately from the other information submitted under subsection (a) and designates such separately listed information as funding for clinical research;

`(vii) contains any other information the Secretary determines would be helpful to the average consumer; and

`(viii) provides the covered recipient an opportunity to submit corrections to the information made available to the public with respect to the covered recipient.

`(2) CONSULTATION- In establishing the procedures under paragraph (1), the Secretary shall consult with the Inspector General of the Department of Health and Human Services, affected industry, consumers, consumer advocates, and other interested parties in order to ensure that the information made available to the public under such paragraph is presented in the appropriate overall context.

`(d) Annual Reports and Relation to State Laws-

`(1) ANNUAL REPORT TO CONGRESS- Not later than April 1 of each year beginning with 2011, the Secretary shall submit to Congress a report that includes the following:

`(A) The information submitted under subsection (a) during the preceding year, aggregated for each applicable manufacturer and applicable group purchasing organization that submitted such information during such year.

`(B) A description of any enforcement actions taken to carry out this section, including any penalties imposed under subsection (b), during the preceding year.

`(2) ANNUAL REPORTS TO STATES- Not later than April 1 of each year beginning with 2011, the Secretary shall submit to States a report that includes a summary of the information submitted under subsection (a) during the preceding year with respect to covered recipients in the State.

`(3) RELATION TO STATE LAWS-

`(A) IN GENERAL- Effective on January 1, 2010, subject to subparagraph (B), the provisions of this section shall preempt any law or regulation of a State or of a political subdivision of a State that requires an applicable manufacturer (as defined in subsection (g)) to disclose or report information (as described in subsection (a)) regarding a payment or other transfer of value provided by the applicable manufacturer to a covered recipient (as so described).

`(B) NO PREEMPTION OF ADDITIONAL REQUIREMENTS- Subparagraph (A) shall not preempt any law or regulation of a State or of a political subdivision of a State that requires the disclosure or reporting of information not required to be disclosed or reported under this section.

`(e) Delayed Reporting for Payments Made Pursuant to Product Development Agreements and Clinical Investigations- In the case of a payment or other transfer of value made to a covered recipient by an applicable manufacturer pursuant to a product development agreement for services furnished in connection with the development of a new drug, device, biological, or medical supply, or by an applicable manufacturer in connection with a clinical investigation, the applicable manufacturer may report the value of such payment or other transfer of value in the first reporting period under subsection (a) after the earlier of the following:

`(1) The date of the approval or clearance of the covered drug, device, biological, or medical supply by the Food and Drug Administration.

`(2) Two calendar years after the date such payment or other transfer of value was made.

`(f) Implementation-

`(1) CONSULTATION- The Secretary shall consult with the Inspector General of the Department of Health and Human Services on the implementation of this section.

`(2) LIMITATION ON REVIEW- There shall be no judicial review of the implementation of this section.

`(g) Definitions- In this section:

`(1) APPLICABLE GROUP PURCHASING ORGANIZATION- The term `applicable group purchasing organization' means a group purchasing organization (as defined by the Secretary) that purchases, arranges for, or negotiates the purchase of a covered drug, device, biological, or medical supply.

`(2) APPLICABLE MANUFACTURER- The term `applicable manufacturer' means a manufacturer of a covered drug, device, biological, or medical supply.

`(3) CLINICAL INVESTIGATION- The term `clinical investigation' means any experiment involving 1 or more human subjects in which a drug or device is administered, dispensed, or used.

`(4) COVERED DEVICE- The term `covered device' means any device for which payment is available under title XVIII or a State plan under title XIX or XXI (or a waiver of such a plan).

`(5) COVERED DRUG, DEVICE, BIOLOGICAL, OR MEDICAL SUPPLY- The term `covered drug, device, biological, or medical supply' means any drug, biological product, device, or medical supply for which payment is available under title XVIII or a State plan under title XIX or XXI (or a waiver of such a plan).

`(6) COVERED RECIPIENT- The term `covered recipient' means the following:

`(A) A physician.

`(B) A physician medical practice.

`(C) A physician group practice.

`(7) EMPLOYEE- The term `employee' has the meaning given such term in section 1877(h)(2).

`(8) KNOWINGLY- The term `knowingly' has the meaning given such term in section 3729(b) of title 31, United States Code.

`(9) MANUFACTURER OF A COVERED DRUG, DEVICE, BIOLOGICAL, OR MEDICAL SUPPLY- The term `manufacturer of a covered drug, device, biological, or medical supply' means any entity which is engaged in the production, preparation, propagation, compounding, conversion, processing, marketing, or distribution of a covered drug, device, biological, or medical supply (or any subsidiary of or entity affiliated with such entity).

`(10) PAYMENT OR OTHER TRANSFER OF VALUE-

`(A) IN GENERAL- The term `payment or other transfer of value' means a transfer of anything of value and includes, subject to subparagraph (B), without limitation, any compensation, gift, honorarium, speaking fee, consulting fee, travel, services, dividend, profit distribution, stock or stock option grant, or ownership or investment interest.

`(B) EXCLUSIONS- An applicable manufacturer shall not be required to submit information under subsection (a) with respect to the following:

`(i) Any payment or other transfer of value provided by an applicable manufacturer to a covered recipient where the aggregate amount transferred to, requested by, or designated on behalf of the covered recipient does not exceed $100 during the calendar year. Such aggregate amount shall be determined without taking into account any payment or other transfer of value described in clauses (ii) through (ix).

`(ii) Product samples that are not intended to be sold and are intended for patient use.

`(iii) Educational materials that directly benefit patients or are intended for patient use.

`(iv) The loan of a covered device for a short-term trial period, not to exceed 90 days, to permit evaluation of the covered device by the covered recipient.

`(v) Items or services provided under a contractual warranty, including the replacement of a covered device, where the terms of the warranty are set forth in the purchase or lease agreement for the covered device.

`(vi) A transfer of anything of value to a covered recipient when the covered recipient is a patient and not acting in the professional capacity of a covered recipient.

`(vii) Discounts (including rebates).

`(viii) In-kind items used for the provision of charity care.

`(ix) A dividend or other profit distribution from, or ownership or investment interest in, a publicly traded security and mutual fund (as described in section 1877(c)).

`(11) PHYSICIAN- The term `physician' has the meaning given that term in section 1861(r). For purposes of this section, such term does not include a physician who is an employee of the applicable manufacturer that is required to submit information under subsection (a).'.

HR 5605: Physicians Payments Sunshine Act Of 2008

It looks like Pharma with their Multi Billion Dollar Psych Hustle MAY be needing some consoling, because HR 5605 might be a WIN for America.

Red Orbit has:

Doctors Gifts Must Be Disclosed Under New Measure

"Kohl said he was confident the legislation, called the Physician Payment Sunshine Act, would pass in the current Democratic-led Congress."

Having to Actually Disclose all that Grease they've been spreading around might leave Pharma themselves Diagnosably 'Clinically Depressed'. And then They would have be subjected to their Own Antidepressing, Antipsychoticing Chemical horrors, with perhaps a side order of Forced ECT (1) 'Treatments'.

The Prescription Project has:

What the Sunshine Act Means.

Downside? 2 More years till it kicks in.

"Where will reports be published?

On a public, searchable website, no later than September 30, 2011."

Here's the text of HR 5605: LINK

In Sept 2007 S. 2029 was a Senate proposal to address the problem.

Being libertarian We're addicted to the adage that America needs JUST 1 MORE LAW:

'No new law may be passed without 1st Revoking 6 existing laws.'

Congress could haply Continue pork-barreling America for another 29 years before that law would even Lipstick their piggie bank. However: given the LETHAL corruption in Academic and Corporate Medicine today - Especially Psychiatry - HR 5605 appears to be desperately needed, and until Constitutionally Mandated Inalienable Rights/Real Free Markets blow that LETHAL Psychiatric Corruption clean Out of medicine, We'll (reluctantly) Endorse this proposed can of Life Saving Tire Patch.

We're reluctant only in that HR 5605 doesn't go far enough. With the Hundreds of Billions in Pharma's cash boxes: $Million Dollar Fines are barely a slap on the wrist.


But then, ..... Rome wasn't built in a day.

Getting It In The Neck: $19 Million to 1 Doctor

This one's Not about Psychs, BUT: ..... it Is about the system which ALLOW$ our plague of TAKE THE DRUG MONEY 'Mental Health' Ideates to go Spook Busting in Your Mind by Profitably Poisoning Your Brain, Body, and Life.

News Inferno has:

Medtronic Paid Researcher $19 Million To Develop, Promote, Infuse Bone Graft, Other Products

And: Once Ahhh, ..... (financial) Gain, we have OFF LABEL, as well as 3 Whistle Blower Suits and Justice Dept. Investigation. The $19 Million came in over 5 years, and Wisconsin's Institution of Higher COI Learning required disclosure of payments in excess of $20K, so the Ethical Dr reported that he received over $20K per year, in 4 years, ..... and that he reeled in More than a whopping $40K in the remaining year, ....... while bagging $19 Million.

News Inferno further links you to Parker Waichman Alonso LLP, who have:

Study Finds Infuse Bone Graft Frequently (17%) Used Off Label (with Problems like DEATH when using it in Neck Surgery) Just what you Don't Need, when you Do need Neck Surgery: a $19 Million Dollar COI.

Talk about "Getting It In The Neck."

Parker Waichman Alonso LLP also have :

FDA Scientist To Obama: Fix Corrupt Agency

"It’s confirmed. The Food & Drug Administration (FDA) is rife with corruption. "

With a Lead in like That, ...... How can you Not read the article?


One Word, ..... and it's unprintable with Ladies and Kids reading.

One Hope, ..... That the alleged Malfeasants Get A Fair Trial.

One Cent, ..... See Above.

Karen Dineen Wagner: TMAP: NARSAD

In Sept the WSJ Health blog had:

Sen Grassley Blasts Psychiatrist For Failure To Disclose Industry Funding

Sen Grassley's detractors have tasked him with grandstanding. Dr Wagner isn't part of the Millionaire Club. She weighs in at a bantam $150,000.

Dr Wagner was part of TMAP, (AHRP) and its health wrecking, national economy busting, chutes and ladders.

"Dr. Wagner served on the Texas Medication Algorithm Project (TMAP) panel whose treatment recommendations are not borne out by the scientific evidence. TMAP was financed by the manufacturers of psychotropic drugs - in states that have adopted TMAP as their guideline, its list of recommended drugs is mandated by state mental health agencies. [5]

Dr. Wagner were hired by the state of Texas to make recommendations to the state mental health department for the treatment of depressed children. They recommended using the very drugs they knew to have serious risks without a demonstrable benefit greater than a sugar pill for children-as first line treatment in state funded facilities. Both Dr. Emslie's and Dr. Wagner's TMAP recommendations are not based on scientific evidence - but rather the consensus of the panel who was financed by psychotropic drug manufacturers."

Allan Jones Full Whistleblower Report

psychrights.org/last item. If you've BTDT, ..... look again/pg 11

"These drug makers all manufacture TMAP depression medications, including Paxil, Prozac, Remeron, Wellbutron and Effexor.

The panel also included Dr Karen Dineen Wagner. In the Aug. 27 Journal of the American Medical Association, Wagner reported on a Pfizer-funded study conducted by Wagner and colleagues at the University of Texas Medical Branch in Galveston. Wagner reported that the Pfizer SSRI Zoloft was safe, effective and well tolerated in children.

Increadibly, this claim was made in the wake of UK bans on the use of Paxil and Effexor (SSRI’s) in children, when both the FDA and the British Committee on Safety in Medicines announced that they were re-examining all SSRI clinical trial data.

An article by Fred Gardner in Drugnews, published on September 3, 2003 critiques the report and offers the following information about Dr.Wagner:

"Dr Wagner has received research support from Abbott, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Glaxo Smith Kline, Organon, Pfizer, and Wyeth-Ayerst; has served as a National Institute of Mental Health consultant to Abbott, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories, Glaxo Smith Kline, Novartis, Otsuka, Janssen, Pfizer,and UCB Pharma; and has participated in speaker's bureaus for Abbott, Eli Lilly, Glaxo Smith Kline, Forest Laboratories, Pfizer, and Novartis.”

The article states:
“What we have here is a case study in how pharmaceutical companies respond to warnings that their products cause harm. Earlier this summer British health authorities advised against treating children and teenagers with Paxil because it triggers suicidal thinking and actual suicide attempts. Zoloft (which is Pfizer's name for a chemical called "sertraline") affects the same receptor system, and is evidently just as dangerous.”

BaumHedlund Law: 2005. In 2002 the BBC covered mounting UK awareness of increased suicide risk from SSRIs.

"The broadcaster received unprecedented response: over 65,000 telephone calls and 1,500 e-mails, largely from SSRI users who had suffered adverse reactions to the drugs."

Check psychsearch.net's listing of Lawsuits which TMAP with its State mandated 1st line Antipsychotics 'Treatments' have resulted in.

Now: does Anyone, ..... Still want to believe that Senator Grassley's interest in Dr Wagner is mere "grandstanding"?

Karen Dineen Wagner, NARSAD Scientific Council: where 300/60 = 1 in 4 (backstory 2007 Annual Report/pg 4/lower right)

NARSAD can hand out over $11 Million a year, for 22 years, to tag and bag "diseased" 1st Amendment Violators, ..... but they can't afford $2.99 for calculator batteries.

Correction:

That report has 1 in Every 4 Adults as having a 'Diagnosable Mental Illness'. Their calculator batteries are fine. It's the batteries in their Moral calculator which are extruding flowers of chemical corruption.

Wisconsin Says NO, To Dr. Freebies

Wisconsin Medical Society Discourages Gifts From Drug Firms

Steven Bergin Shoots, and Scores!

"The Wisconsin Medical Society's board has come out against doctors accepting gifts, speaking fees and other payments from pharmaceutical and medical device companies.

The new policy ranges from the ubiquitous pens and pads found throughout doctors' offices to the controversial practice of paying doctors to give talks about a company's products.

It also includes the free lunches and other food that pharmaceutical sales representatives bring for doctors and their staffs on sales calls.

The Wisconsin Medical Society's policy goes beyond the guidelines of the American Medical Society and most state medical societies.

"We have chosen to take a firm stand," said Steven Bergin, president of the Wisconsin Medical Society. "

The Wisconsin Medical Society represents roughly 2/3 of Wisconsin's Doctors. This article says that PhRMA and Med Device Cos. spend about $19 Billion annually Greasing Doctors.

[Backstory This time is By The Numbers]

With That kind of Money chumming the Patient pool, do you Really think for a second, ..... that You, Mr & Mrs patient, ..... have a Wounded Mackerel's Chance in That Pool, of BEING SOLD, the chemical or implant that's "Right For You" (1) based solely on the impartial objectivity of your "Caregiving Healthcare Provider", who May or May Not be drunk or doped up (2) themselves, and qualifying for Kid Glove 'Get Out Of Jail Free' (3) State sponsored Physician Diversion Rehab, on any given day?

And Speaking of, ..... Does Anyone know what actually happened to California's Drunk, and 'Mentally Ill', (read Spoiled Brat) Dr. (4) Cover Up Program? It was so overwhelmed with its inability to even Window Dress the problem, that it scheduled Itself for Suicide on June 30, 2008, but, if so, it must have just quietly hanged itself in the closet.

And to those who say that Freebies are no big deal, ..... How do you think we got to this Tsunami of Brain & CNS damaging Antipsychotics Poisoning 80% or more of the kids in Florida's foster care system? (5)

Health Care Renewal brought us a page (6) Re: KOL Dr. Charles Nemeroff, and his personal mastery of Industry Freebies.

YIKES!

PS: One For The Road: Evelyn Pringle's new in depth report: (7) Part 1 on "Pharmaceutical Industry Hustlers". The Hat Tip here goes to Fid @ seroxat sufferers.